<DOC>
	<DOCNO>NCT00822809</DOCNO>
	<brief_summary>This randomized phase IIIb study investigate treatment malignant ascites due epithelial cancer ( carcinoma ) trifunctional antibody catumaxomab . In order make catumaxomab treatment convenient patient hospital praxis tolerability 3 hour infusion catumaxomab without premedication prednisolone evaluate . A total 208 patient malignant ascites due epithelial cancer allocate two treatment group 1:1 ratio .</brief_summary>
	<brief_title>CASIMAS : Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion Patients With Malignant Ascites Due Epithelial Cancers</brief_title>
	<detailed_description>Safety data complete pivotal phase II/III trial , IP-REM-AC-01 , catumaxomab administer 6 hour i.p . infusion show report AEs cytokine release-related symptom fever , nausea , vomit ( base pharmacodynamic mode action catumaxomab ) abdominal pain . In order make catumaxomab treatment convenient patient hospital praxis current trial design determine whether tolerability 3 hour infusion catumaxomab without premedication prednisolone . Prednisolone choose additional premedication objective reduce cytokine release relate symptom might change switch 6 3 h infusion time .</detailed_description>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Key 1 . Patients malignant ascites require therapeutic ascites puncture 2 . Histological confirm diagnosis epithelial cancer 3 . Patients standard therapy available longer feasible 4 . Karnofsky index â‰¥60 % 5 . Life expectancy &gt; 12 week Key 1 . Concomitant treatment investigational product , chemo , radiotherapy 2 . Recent exposure investigational product 3 . Known suspected hypersensitivity catumaxomab similar antibody 4 . Inadequate respiratory , renal hepatic function 5 . Inadequate blood count ( platelet , neutrophil ) 6 . Required entirely parenteral nutrition 7 . Patients ileus subileus within last 30 day 8 . Liver metastasis volume &gt; 70 % liver tissue 9 . Known portal vein obstruction 10 . Known Brain metastases 11 . Acute chronic infection 12 . Not sufficiently recover previous treatment ( toxicity present ) base laboratory value general status 13 . Albumin low 3 g/dL total protein &lt; 6g/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Malignant Ascites</keyword>
	<keyword>Drug therapy</keyword>
	<keyword>Antineoplastic Protocols</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Phase III</keyword>
	<keyword>trifunctional antibody</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>EpCAM</keyword>
</DOC>